Dr. Kaminski’s team main ambition is to uncover the mechanisms, and thus have a significant impact on the management of advanced lung diseases with a specific focus on IPF, a chronic progressive interstitial lung disease that is currently incurable. 

To study these mechanisms Dr. Kaminski’s team applies systems biology approaches that incorporate a combination of traditional molecular biology methods, high-throughput genomic technologies such as transcript level profiling (microarrays and next generation sequencing) of coding and non-coding RNA, genome scale analyses of gene variants, advanced bioinformatics approaches and targeted proteomic approaches. 

These studies have led to shifts in the perception of pulmonary fibrosis, the realization that aberrant activation of developmental pathways is at the core of lung fibrosis, the discovery of the role of microRNAs in IPF, the identification and validation of novel prognostic biomarkers in the bloodstream, as well many additional insights.

Basic Mechanisms

Understanding and identifying the genetic and molecular networks that determine the lung phenotype using high throughput genomic and proteomic technologies.

  • Role of microRNAs in Idiopathic Pulmonary Fibrosis and other chronic lung disease
  • Role of other non-coding RNAs (lincRNAs) in advanced lung disease
  • Epigenomic regulation of cellular phenotypes in chronic lung disease
  • The role of developmental pathways in lung injury and aberrant repair (scaring)
  • Role of the microbiome in defining lung phenotypes in chronic lung disease
  • The molecular basis of Cellular and Regional Heterogeneity in the IPF lung

New Molecular Targets

  • The role and regulation of matrix metaloproteases (MMP7, MMP19) in human pulmonary fibrosis.
  • Development of microRNA based interventions (let-7, mir-29, mir-30, mir-154 families) for therapy in human Pulmonary Fibrosis
  • Mechanisms and regulation of lincRNA perturbations in IPF
  • Using high throughput ‘omics’ data to facilitate the implementation of novel therapies in Lung Fibrosis
  • Application of single cell approaches to better assess efficacy of therapeutic interventions in IPF

Personalized Medicine

  • Molecular Phenotyping of Chronic Lung Disease
    • Molecular diagnosis of IPF
    • Computational approaches to Integrate clinical, biological, genomic and proteomic data
  • Use of surrogate tissues to diagnose and manage chronic lung disease
    • Peripheral blood protein markers to diagnose and predict outcome in Lung Fibrosis
    • Peripheral Blood Gene Expression patterns
    • Circulating microRNAs reflect organ phenotype and disease presence and outcome
    • Markers and predictors of target engagement and response to therapy
  • Genetic Markers
    • Disease predisposition
    • Outcome prediction
    • Response to therapy

Non-Coding RNA

  • The role and regulation of matrix metalloproteases (MMP7, MMP19) in human pulmonary fibrosis
  • The role and regulation of microRNAs (let-7, mir-30, mir-154 families) in human pulmonary fibrosis